ストックスクリーナーアプリを入手
1.45
1.40%
0.02
アフターアワーズ：
1.40
-0.05
-3.45%
前日終値:
$1.43
開ける：
$1.45
24時間の取引高:
587.62K
Relative Volume:
0.72
時価総額：
$72.03M
収益：
$300.00K
当期純損益:
$-27.61M
株価収益率:
-2.51
EPS:
-0.5777
ネットキャッシュフロー:
$-22.17M
1週間 パフォーマンス:
+3.57%
1か月 パフォーマンス:
+5.07%
6か月 パフォーマンス:
-36.68%
1年 パフォーマンス:
+95.63%
1日の値動き範囲:
$1.4226
$1.475
1週間の範囲:
$1.34
$1.54
52週間の値動き範囲:
$0.67
$3.82
iBio Inc Stock (IBIO) Company Profile
Compare IBIO vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
1.45 | 71.04M | 300.00K | -27.61M | -22.17M | -0.5777 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-06-08 | 開始されました | Raymond James | Outperform |
| 2026-06-05 | 開始されました | B. Riley Securities | Buy |
| 2025-10-21 | 開始されました | Oppenheimer | Outperform |
| 2025-10-17 | 開始されました | Leerink Partners | Outperform |
| 2024-05-28 | 開始されました | Chardan Capital Markets | Buy |
| 2021-11-29 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-01-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-06-26 | 開始されました | Alliance Global Partners | Buy |
すべてを表示
iBio Inc (IBIO) 最新ニュース
iBio (NASDAQ:IBIO) Rating Increased to Hold at Wall Street Zen - MarketBeat
Lynx1 Capital Management (IBIO) corrects 5.4% iBio stake including 2.8M warrant shares - Stock Titan
Vestal Point Capital (IBIO) discloses 4.0M-share iBio position including warrants - Stock Titan
Cormorant Asset Management (IBIO) discloses 9.99% iBio stake via stock and warrants - Stock Titan
Affinity Asset Advisors (IBIO) discloses 5.07M-share, 9.99% stake in iBio - Stock Titan
iBio Inc (IBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
iBio, Inc. (NASDAQ:IBIO) Given Average Rating of "Buy" by Analysts - MarketBeat
iBio Inc (IBIO) Stock News Today - TradingKey
NAGE Stock Price and Chart — NASDAQ:NAGE - TradingView
iBio Appoints Molly Carr as Chief Medical Officer - The Globe and Mail
iBio Expands Must-have Cardiometabolic and Obesity Pipeline Investor through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio - Diario AS
IBIO 8-K & SEC Filings - Yahoo Finance
iBio Inc. (IBIO) Edges Higher by 2.82% as Shares Test Key Resistance ZoneATR Trailing Stop - dars.gov.et
iBio (IBIO) awards 430,000 stock options to its Chief Medical Officer - Stock Titan
iBio appoints Molly Carr as chief medical officer By Investing.com - Investing.com India
iBio appoints Molly Carr as chief medical officer - Investing.com
Molly Carr named Chief Medical Officer at iBio - TradingView
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer - Yahoo Finance
iBio Inc (IBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
iBio Inc (IBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
iBio Inc (IBIO) Balance Sheet - TradingKey
iBio Inc (IBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
iBio Inc (IBIO) Cash Flow - TradingKey
iBio Inc (IBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
iBio Inc (IBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IBIO|iBio Inc|Price:1.385|Chg%:-0.065 - TradingKey
iBio Inc (IBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IBIO Q2 2026 Earnings: Narrower Loss Beats Estimates; Pre-Revenue Status Remains ClearGuidance Accuracy Score - po-news-eg.net
iBio, Inc. Revenue Breakdown – TRADEGATE:0JV0 - TradingView
TradingKey - TradingKey
Affinity Asset Advisors LLC Grows Position in iBio, Inc. $IBIO - MarketBeat
IBIO|iBio Inc|Price:1.430|Chg%:+0.030 - TradingKey
iBio Inc (IBIO) Institutional Confidence - TradingKey
iBio Inc. (IBIO) Slips 1.09% as Biotech Sector Faces Headwinds – Key Support at $1.29 in FocusUndervalued Stocks - dars.gov.et
Chardan Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
iBio Updates Governance Deadlines for 2026 Annual Meeting - The Globe and Mail
iBio (NYSE: IBIO) schedules 2026 meeting, updates proposal deadlines - Stock Titan
iBio, Inc. (NASDAQ:IBIO) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
iBio (NASDAQ:IBIO) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
iBio Inc. Holds Steady at $1.51 as Biotech Stock Consolidates Near Key LevelsSupply Zone - dars.gov.et
We Think iBio (NASDAQ:IBIO) Can Afford To Drive Business Growth - Sahm
iBio Inc. (IBIO) Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pre‑Revenue PhaseBanking Earnings Report - DonanımHaber
iBio Inc. (IBIO) Retreats 1.85%, Approaching Key Support at $1.51Narrow Range Breakout - DonanımHaber
Price to sales forward of iBio, Inc. – NASDAQ:IBIO - TradingView
Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO) - The Globe and Mail
IBIO Maintained by Chardan Capital -- Price Target Stays at $5.0 - GuruFocus
IBIO News | IBIO INC (NASDAQ:IBIO) - ChartMill
IBIOiBio Inc Latest SEC Filings - Finviz
$IBIO stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
iBio’s IBIO-610 Antibody Achieves 98% Activin E Inhibition and Boosts Fat Loss in Obese Primates, Outperforming Semaglutide Alone 1 - Minichart
iBio Highlights Promising New Preclinical Obesity Antibody Data - TipRanks
iBio Inc (IBIO) 財務データ
収益
当期純利益
現金流量
EPS
iBio Inc (IBIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Duran Felipe | Chief Financial Officer |
Mar 19 '26 |
Buy |
2.02 |
24,835 |
50,132 |
35,974 |
| Brenner Martin | See Remarks |
Mar 19 '26 |
Buy |
2.02 |
12,336 |
24,919 |
30,652 |
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):